This Digital Dialogue examined the current state of DHT use in clinical trials, with a focus on addressing the practical, regulatory, and scientific barriers limiting broader uptake. 

We were joined by five leaders in the Clinical space who highlighted the role of digital health technologies (DHTs), with particular emphasis on cross-sector collaborations driving real-world clinical trial impact.

Speakers

• Jarjieh Fang, Director, HVE, Patient-Centered Outcomes Assessment, Pfizer
• Jay Trudeau, Senior Director, Eli Lilly & Co
• Marie McCarthy, Digital Endpoint Lead Director, Novartis
• Farrell Healion, Founder and Principal Consultant, OptiTrial
• Scottie Kern, Executive Director, eCOA Consortium, C-Path

To watch the discussion please fill out the form below.